Welcome to Legit.Health's Data Room
This space gathers the operational, financial, and regulatory documentation Legit.Health makes available to potential investors during due diligence. All sections are versioned and updated regularly.
The proposition
Legit.Health is a clinical AI platform with €300K ARR (+83% YoY) within a hybrid revenue model that generated €604K recognised revenue and €848K in billings during 2025 (+145% YoY).
Currently raising a bridge round of €1.5M-€2.0M to take ARR from €300K to €1M by EoY 2026, after which a Series A is planned at materially improved terms.
Key metrics 2025
Company snapshot
Bridge Round in progress
A Bridge round of €1.5M-€2.0M is currently in process, targeting close in Q2 2026. Existing investors (Mutua Ventures, Telefónica Open Innovation, Ribera Salud, Biozell Ventures, Angels Capital, Sanitas) have been informed and are evaluating participation. SAFE/convertible structure with cap referenced to future Series A.
Bridge use of funds: ~45% commercial expansion (BUPA Europe, pharma frames, customer success) · ~25% FDA + US regulatory · ~20% runway buffer to Q2 2027 · ~10% operations.
Series A planned post-bridge: targeted H2 2026 / H1 2027 at €15-20M+ pre-money, once Bridge milestones (€1M ARR, FDA pre-sub, 2+ pharma frames) are hit.